Belite Bio CSO sells 1,000 ADS in planned trade
Belite Bio Chief Scientific Officer Nathan L. Mata reported selling a total of 1,000 American depositary shares in open-market transactions.
Rhea-AI Filing Summary
Belite Bio Chief Scientific Officer Nathan L. Mata reported selling a total of 1,000 American depositary shares in open-market transactions. The sales occurred on April 27, 2026 at prices ranging from about $160.83 to $164.07 per share. Following these trades, he directly holds 7,666 American depositary shares, each representing one ordinary share of Belite Bio. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on 12/10/2025, indicating the sales were scheduled in advance rather than timed discretionarily.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | American depositary share | 44 | $160.8345 | $7K |
| Sale | American depositary share | 280 | $161.6211 | $45K |
| Sale | American depositary share | 231 | $162.3775 | $38K |
| Sale | American depositary share | 409 | $163.5573 | $67K |
| Sale | American depositary share | 36 | $164.0717 | $6K |
Footnotes (7)
- F1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
- F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
- F3. Represents the weighted average price of shares sold at prices that ranged from $160.54 to $160.95. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F4. Represents the weighted average price of shares sold at prices that ranged from $161.075 to $161.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F5. Represents the weighted average price of shares sold at prices that ranged from $162 to $162.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F6. Represents the weighted average price of shares sold at prices that ranged from $163 to $163.995. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
- F7. Represents the weighted average price of shares sold at prices that ranged from $164 to $164.59. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
open-market sale financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Belite Bio (BLTE) insider Nathan L. Mata do in this Form 4?
Was the Belite Bio (BLTE) insider sale made under a Rule 10b5-1 plan?
What type of security did Belite Bio (BLTE) insider Nathan L. Mata sell?
AI-generated analysis. How Rhea-AI works. Not financial advice.